Phencyclidine (PCP) withdrawal

Phencyclidine (PCP) withdrawal occurs when a person who has been using PCP, a powerful hallucinogenic drug, suddenly stops or reduces their intake. This condition primarily affects the nervous system, leading to a range of symptoms that can impact mental and physical health. Common symptoms include anxiety, agitation, and confusion, which reflect the brain's response to the absence of the drug. Other effects may involve tremors, sweating, and difficulty sleeping. These symptoms arise because the brain has adapted to the presence of PCP, and withdrawal disrupts this balance. Understanding withdrawal is important for recognizing the challenges faced during recovery from PCP use.

Phencyclidine (PCP) withdrawal is a clinical syndrome that occurs after abrupt cessation or reduction of chronic PCP use, a dissociative anesthetic that acts primarily as an NMDA receptor antagonist. The core pathology involves neurochemical imbalances in the central nervous system due to the sudden absence of PCP's effects on glutamatergic neurotransmission. This leads to a hyperexcitable state manifesting as psychomotor agitation, anxiety, delirium, and autonomic instability. The condition is significant because withdrawal symptoms can mimic acute psychiatric or neurological disorders, complicating diagnosis and management. Withdrawal typically develops within hours to days after stopping PCP and can last for several days. Recognition of this syndrome is critical in patients with a history of PCP use presenting with neuropsychiatric symptoms.